F2R and myocardial infarction: In the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P)–Thrombolysis in Myocardial Infarction (TIMI) 50 trial, 26,449 patients were enrolled after myocardial infarction, with PAD or after stroke (29).